西安秦申嘉合药物研究

Xi'an Qinshen Jiahe Pharmaceutical Research is a China-based biopharmaceutical company dedicated to the research and development of innovative small molecule therapeutics. The company's primary therapeutic focus is neurology, specifically targeting cerebrovascular diseases. Its lead clinical candidate, YZD-27, is a Class 1 innovative chemical drug currently undergoing Phase 1 clinical trials for the treatment of acute ischemic stroke (AIS). YZD-27 functions by increasing cerebral blood perfusion and promoting the recovery of blood flow in the ischemic penumbra to provide anti-cerebral ischemic protection. Headquartered in Xi'an, Shaanxi Province, the company leverages advanced drug discovery capabilities to address significant unmet medical needs in central nervous system disorders.